Boston Scientific Corporation $BSX Stock: Goelzer Investment Management Inc. Raises Position

Goelzer Investment Management Inc. lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 287.8% during the third quarter, Holdings Channel reports. The fund owned 49,215 shares of the medical equipment provider’s stock after purchasing an additional 36,524 shares during the quarter. Goelzer Investment Management Inc.’s holdings in Boston Scientific were worth $2,148,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Perigon Wealth Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $883,000. Y Intercept Hong Kong Ltd raised its position in shares of Boston Scientific by 148.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after buying an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in shares of Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after buying an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $38,539,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig purchased 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Mizuho set a $55.00 target price on shares of Boston Scientific in a research note on Tuesday. Needham & Company LLC cut their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Piper Sandler reduced their price target on Boston Scientific from $65.00 to $60.00 in a research note on Wednesday, July 29th. Finally, Citigroup decreased their price objective on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating on the stock in a report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Trading Up 0.5%

NYSE BSX opened at $44.34 on Friday. The company has a market cap of $64.26 billion, a P/E ratio of 17.95, a P/E/G ratio of 1.07 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a 50-day moving average of $46.06 and a 200-day moving average of $49.76.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.